

October 19, 2015
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

SymBio to Participate in Global Phase 3 Trial for IV Rigosertib

TOKYO, Japan, October 19, 2015 --- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that it has made the decision to participate in the global Phase 3 trial (“04-30” or “INSPIRE” trial) for the IV formulation of rigosertib planned to be initiated by its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, “Onconova”) this year, in accordance with an agreement the Company has reached with Japan’s PMDA (Pharmaceuticals and Medical Devices Agency).

SymBio expects to complete its ongoing Phase 1 trial for IV rigosertib (SyB L-1101) in Japan to treat relapsed or refractory higher-risk myelodysplastic syndromes (HR-MDS) patients in October, 2015, prior to its participation in the global Phase 3 trial.

Onconova has filed Clinical Trial Applications (CTAs) with several regulatory agencies in Europe and an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for IV rigosertib as a treatment in HR-MDS patients after failure of a hypomethylating agent (HMA) therapy.

Participation in the global Phase 3 trial will not impact the Company’s financial forecast for FY2015.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and autoimmune disease.